Melatonin for the management of preeclampsia: A review

Annie Langston‐cox, Sarah A. Marshall, Daisy Lu, Kirsten R. Palmer, Euan M. Wallace

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Preeclampsia is a disease specific to pregnancy characterised by new‐onset hypertension with maternal organ dysfunction and/or fetal growth restriction. It remains a major cause of maternal and perinatal morbidity and mortality. For sixty years, antihypertensives have been the main-stay of treating preeclampsia and only recently have insights into the pathogenesis of the disease opened new avenues for novel therapies. Melatonin is one such option, an endogenous and safe antioxidant, that may improve the maternal condition in preeclampsia while protecting the fetus from a hostile intrauterine environment. Here we review the evidence for melatonin as a possible adjuvant therapy for preeclampsia, including in vitro evidence supporting a role for melatonin in protecting the human placenta, preclinical models, vascular studies, and clinical studies in hypertension and pregnancy.

Original languageEnglish
Article number376
Number of pages17
JournalAntioxidants
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 2021

Keywords

  • Antioxidant
  • Melatonin
  • Mitochondrial function
  • Placental biology
  • Preeclampsia

Cite this